Pouyan Ebrahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pouyan Ebrahimi has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Amin Esmaeilnia Shirvani
School of Medicine, Babol University of Medical Sciences, Babol, Iran
9 shared publications - Kimia Pakdaman
Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran
9 shared publications - Hossein-Ali Nikbakht
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
8 shared publications Kimia Pakdaman
Student Research Committee, Babol University of Medical Science, Babol, Iran
6 shared publications- Kasra Pakdaman
School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran
5 shared publications - Seyed Hassan Abedi
Department of Medicine, Babol University of Medical Sciences, Babol, Iran
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in BMC Cancer
Incidence and molecular subtype patterns of lung metastases in breast cancer: a systematic review and meta-analysis
Background: Lung metastasis (LM) is a clinically significant manifestation of breast cancer (BC), yet its incidence across diverse populations remains insufficiently characterized. This study aimed to estimate the pooled reported proportion of LM and explore potential sources of heterogeneity. Methods: This systematic review and meta-analysis was conducted following PRISMA guidelines and prospectively registered in PROSPERO (CRD420251275241). PubMed, Scopus, Embase, Web of Science, and Google Scholar were systematically searched from inception to September 30, 2026, without language restrictions. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Joanna Briggs Institute checklist. Pooled LM proportions were estimated using a random-effects model with restricted maximum likelihood (REML) estimation and logit-transformed proportions. Subgroup analyses, meta-regression, and sensitivity analyses were performed to explore heterogeneity and assess the robustness of the findings. Results: Seventeen studies comprising 1,023,998 BC patients and 10,685 reported LM cases were included. The pooled reported LM proportion was 2.68% (95% CI: 1.40–5.07%), with substantial heterogeneity (I² = 99.87%). Subtype-specific pooled point estimates were 4.53% for HR−/HER2+, 3.86% for TNBC, 2.22% for HR+/HER2+, and 1.33% for HR+/HER2 − disease; however, the overall between-subgroup difference was not statistically significant ( p = 0.520). Subgroup analyses revealed significant differences across WHO regions ( p < 0.001), PM2.5 categories ( p = 0.002), and risk-of-bias classifications ( p = 0.012), whereas HDI, income level, study design, and publication year showed no significant between-group differences. The six primary moderators showed no significant associations in univariable meta-regression. Despite significant differences across PM2.5 categories in subgroup analyses, neither continuous PM2.5 nor AQI was significantly associated with LM proportion in the exploratory multivariable model (PM2.5: β = −0.272, p = 0.317; AQI: β = 0.108, p = 0.389). An inverse association between HDI and the reported LM proportion emerged only in the exploratory multivariable model (β = −12.924, p = 0.040) and should be interpreted cautiously given the limited number of studies and potential multicollinearity. Conclusion: The pooled reported proportion of LM among BC patients was approximately 2.7%, with considerable heterogeneity across studies. Although geographical and environmental subgroup differences were observed, the inconsistency of study-level associations warrants cautious interpretation. Standardized metastatic-site reporting and improved epidemiological surveillance are essential for more reliable estimates. Clinical trial registration: Not applicable.
- 3 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessIncidence and molecular subtype patterns of lung metastases in breast cancer: a systematic review and meta-analysis
Background: Lung metastasis (LM) is a clinically significant manifestation of breast cancer (BC), yet its incidence across diverse populations remains insufficiently characterized. This study aimed to estimate the pooled reported proportion of LM and explore potential sources of heterogeneity. Methods: This systematic review and meta-analysis was conducted following PRISMA guidelines and prospectively registered in PROSPERO (CRD420251275241). PubMed, Scopus, Embase, Web of Science, and Google Scholar were systematically searched from inception to September 30, 2026, without language restrictions. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Joanna Briggs Institute checklist. Pooled LM proportions were estimated using a random-effects model with restricted maximum likelihood (REML) estimation and logit-transformed proportions. Subgroup analyses, meta-regression, and sensitivity analyses were performed to explore heterogeneity and assess the robustness of the findings. Results: Seventeen studies comprising 1,023,998 BC patients and 10,685 reported LM cases were included. The pooled reported LM proportion was 2.68% (95% CI: 1.40–5.07%), with substantial heterogeneity (I² = 99.87%). Subtype-specific pooled point estimates were 4.53% for HR−/HER2+, 3.86% for TNBC, 2.22% for HR+/HER2+, and 1.33% for HR+/HER2 − disease; however, the overall between-subgroup difference was not statistically significant ( p = 0.520). Subgroup analyses revealed significant differences across WHO regions ( p < 0.001), PM2.5 categories ( p = 0.002), and risk-of-bias classifications ( p = 0.012), whereas HDI, income level, study design, and publication year showed no significant between-group differences. The six primary moderators showed no significant associations in univariable meta-regression. Despite significant differences across PM2.5 categories in subgroup analyses, neither continuous PM2.5 nor AQI was significantly associated with LM proportion in the exploratory multivariable model (PM2.5: β = −0.272, p = 0.317; AQI: β = 0.108, p = 0.389). An inverse association between HDI and the reported LM proportion emerged only in the exploratory multivariable model (β = −12.924, p = 0.040) and should be interpreted cautiously given the limited number of studies and potential multicollinearity. Conclusion: The pooled reported proportion of LM among BC patients was approximately 2.7%, with considerable heterogeneity across studies. Although geographical and environmental subgroup differences were observed, the inconsistency of study-level associations warrants cautious interpretation. Standardized metastatic-site reporting and improved epidemiological surveillance are essential for more reliable estimates. Clinical trial registration: Not applicable.
- Open Access
- 21 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Systematic review and meta-analysis of lung metastases incidence in cervical cancer patients
- 21 July 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessSystematic review and meta-analysis of lung metastases incidence in cervical cancer patients
- Open Access
- 14 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Trends and disparities in unintentional injury mortality among children under five in northern Iran: a 10-year population-based surveillance study (2013–2022)
Although unintentional injuries (UIs) are a well-recognized cause of early childhood mortality, regional evidence on their trends and disparities remains limited in Northern Iran, where subnational variation may obscure national progress. This study investigates the patterns and characteristics of unintentional injury deaths (UIDs) in this vulnerable population. We conducted a retrospective trend study using mortality data from the under-five death (U5D) surveillance system in Northern Iran, covering the years 2013 to 2022. Causes of death were classified according to ICD-10 codes. Temporal trends in UIDs were examined using Join point regression analysis, while Poisson regression was applied to estimate relative risks (RRs) and 95% confidence intervals (CIs) for sex- and residence-based disparities. Among 3390 U5Ds, 240 (7.08%) were attributable to UIs. The overall unintentional injury death (UIDs) rate was 0.81 per 1,000 live births, declining non-significantly from 0.93 in 2013 to 0.52 in 2022 (APC − 3.34%, p = 0.162). Transport accidents were the predominant cause (56.7%), followed by accidental drowning and submersion (10.8%) and other accidental threats to breathing (10.0%). Girls had a significantly lower risk of UIDs rate compared to boys (RR = 0.76; 95% CI: 0.58–0.98). No statistically significant difference was found between rural and urban areas (RR = 1.25; 95% CI: 0.97–1.61). Between 2013 and 2022, UIDs among children under five in Mazandaran Province showed a downward trend; however, the reduction was not statistically significant. During this period, boys consistently exhibited a significantly higher risk of injury-related mortality compared with girls. These patterns underscore persistent inequities in child injury outcomes and highlight the need for sustained, equity-focused preventive strategies, particularly those targeting high-risk groups and the leading mechanisms of injury, such as transport incidents, drowning, and suffocation.
- 14 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessTrends and disparities in unintentional injury mortality among children under five in northern Iran: a 10-year population-based surveillance study (2013–2022)
Although unintentional injuries (UIs) are a well-recognized cause of early childhood mortality, regional evidence on their trends and disparities remains limited in Northern Iran, where subnational variation may obscure national progress. This study investigates the patterns and characteristics of unintentional injury deaths (UIDs) in this vulnerable population. We conducted a retrospective trend study using mortality data from the under-five death (U5D) surveillance system in Northern Iran, covering the years 2013 to 2022. Causes of death were classified according to ICD-10 codes. Temporal trends in UIDs were examined using Join point regression analysis, while Poisson regression was applied to estimate relative risks (RRs) and 95% confidence intervals (CIs) for sex- and residence-based disparities. Among 3390 U5Ds, 240 (7.08%) were attributable to UIs. The overall unintentional injury death (UIDs) rate was 0.81 per 1,000 live births, declining non-significantly from 0.93 in 2013 to 0.52 in 2022 (APC − 3.34%, p = 0.162). Transport accidents were the predominant cause (56.7%), followed by accidental drowning and submersion (10.8%) and other accidental threats to breathing (10.0%). Girls had a significantly lower risk of UIDs rate compared to boys (RR = 0.76; 95% CI: 0.58–0.98). No statistically significant difference was found between rural and urban areas (RR = 1.25; 95% CI: 0.97–1.61). Between 2013 and 2022, UIDs among children under five in Mazandaran Province showed a downward trend; however, the reduction was not statistically significant. During this period, boys consistently exhibited a significantly higher risk of injury-related mortality compared with girls. These patterns underscore persistent inequities in child injury outcomes and highlight the need for sustained, equity-focused preventive strategies, particularly those targeting high-risk groups and the leading mechanisms of injury, such as transport incidents, drowning, and suffocation.
- Open Access
- 7 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2641284
Response to letter regarding comment on “worldwide prevalence of haemorrhoids: a systematic review and meta-analysis”
- 7 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2641284
Open AccessResponse to letter regarding comment on “worldwide prevalence of haemorrhoids: a systematic review and meta-analysis”
- Open Access
- 2 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 327
Efficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials
The integration of immune checkpoint inhibitors with anti-angiogenic therapy has transformed the management of advanced malignancies. Atezolizumab (ATZ), a
- 2 March 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1) , 327
Open AccessEfficacy and safety of atezolizumab combined with bevacizumab-based chemotherapy in advanced malignancies: a systematic review and meta-analysis of randomized trials
The integration of immune checkpoint inhibitors with anti-angiogenic therapy has transformed the management of advanced malignancies. Atezolizumab (ATZ), a
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2026 (1)
A Novel Approach to Recurrent Hepatic Hydatid Cyst Using EUS‐Guided Aspiration and Ethanol Injection: A Case Report and Focused Literature Review
Background: Hepatic hydatid disease, a manifestation of cystic echinococcosis caused by Echinococcus granulosus , remains endemic in many regions and poses a persistent therapeutic challenge. Although surgery is often employed for definitive management, recurrence, procedural risks, and anatomical constraints have led to growing interest in minimally invasive alternatives such as percutaneous aspiration and endoscopic interventions. Case Presentation: We report a 52‐year‐old male with an incidentally detected hepatic hydatid cyst who initially underwent surgical cystectomy and cholecystectomy. Twenty‐five days postoperatively, the patient developed new abdominal fullness, and repeat imaging revealed a cystic lesion in the left hepatic lobe measuring 13.4 × 9.9 cm, reported radiologically as recurrence. The patient underwent endoscopic ultrasound (EUS)–guided fine‐needle aspiration and lavage of the cyst cavity with 20 mL of 96% ethanol. The procedure was well tolerated with no adverse events, and follow‐up imaging at 6 months confirmed complete cyst resolution. Conclusion: This case demonstrates the technical feasibility and clinical safety of EUS‐guided ethanol ablation as a minimally invasive alternative for recurrent hepatic hydatid cysts. It highlights the expanding therapeutic potential of EUS beyond conventional indications and supports further exploration of this technique in selected cases.
- 1 January 2026
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2026 (1)
Open AccessA Novel Approach to Recurrent Hepatic Hydatid Cyst Using EUS‐Guided Aspiration and Ethanol Injection: A Case Report and Focused Literature Review
Background: Hepatic hydatid disease, a manifestation of cystic echinococcosis caused by Echinococcus granulosus , remains endemic in many regions and poses a persistent therapeutic challenge. Although surgery is often employed for definitive management, recurrence, procedural risks, and anatomical constraints have led to growing interest in minimally invasive alternatives such as percutaneous aspiration and endoscopic interventions. Case Presentation: We report a 52‐year‐old male with an incidentally detected hepatic hydatid cyst who initially underwent surgical cystectomy and cholecystectomy. Twenty‐five days postoperatively, the patient developed new abdominal fullness, and repeat imaging revealed a cystic lesion in the left hepatic lobe measuring 13.4 × 9.9 cm, reported radiologically as recurrence. The patient underwent endoscopic ultrasound (EUS)–guided fine‐needle aspiration and lavage of the cyst cavity with 20 mL of 96% ethanol. The procedure was well tolerated with no adverse events, and follow‐up imaging at 6 months confirmed complete cyst resolution. Conclusion: This case demonstrates the technical feasibility and clinical safety of EUS‐guided ethanol ablation as a minimally invasive alternative for recurrent hepatic hydatid cysts. It highlights the expanding therapeutic potential of EUS beyond conventional indications and supports further exploration of this technique in selected cases.
- Open Access
- 27 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Systematic review and meta analysis of the global incidence and clinicopathological characteristics of liver metastasis in patients with cervical cancer
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.
- 27 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessSystematic review and meta analysis of the global incidence and clinicopathological characteristics of liver metastasis in patients with cervical cancer
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.
- Top Cited PapersOpen Access
- 26 December 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2606433
Worldwide prevalence of haemorrhoids: a systematic review and meta-analysis
Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis. We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600). From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension. HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.
- 26 December 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2606433
Top Cited PapersOpen AccessWorldwide prevalence of haemorrhoids: a systematic review and meta-analysis
Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis. We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600). From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension. HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.
- Open Access
- 19 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Global incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women
Stroke is a leading cause of death and disability worldwide, with its prevalence increasing due to risk factors such as hypertension, diabetes, and hyperli
- 19 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessGlobal incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women
Stroke is a leading cause of death and disability worldwide, with its prevalence increasing due to risk factors such as hypertension, diabetes, and hyperli
- Open Access
- 26 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70405
Brain Metastases in Cervical Cancer: A Global Systematic Review and Meta‐Analysis of Incidence and Clinicopathological Features
Background: Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims: Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods: We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results: A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion: Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.
- 26 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70405
Open AccessBrain Metastases in Cervical Cancer: A Global Systematic Review and Meta‐Analysis of Incidence and Clinicopathological Features
Background: Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims: Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods: We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results: A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion: Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.